ASLAN Pharmaceuticals Announces Plan To Implement ADS Ratio Change From 1 ADS Representing 25 Shares To 1 ADS Representing 200 Shares (1-For-8 ADS Split), Effective Date For The Ratio Change, July 3, 2024
ASLAN Pharmaceuticals Announces Plan To Implement ADS Ratio Change From 1 ADS Representing 25 Shares To 1 ADS Representing 200 Shares (1-For-8 ADS Split), Effective Date For The Ratio Change, July 3, 2024
aslan pharmaceuticals宣佈計劃實施ADS比例變更，由1個ADS代表25股變更爲1個ADS代表200股（1：8 ADS分拆），比例變更的生效日期爲2024年7月3日。
ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares ("ADSs") to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares.
aslan pharmaceuticals（“ASLAN”或該公司，納斯達克:ASLN）是一家處於臨床階段、以免疫學爲重點的生物製藥公司，正在開發創新治療方案以改變患者的生命。今天宣佈，計劃將美國存托股份(“ADSs”)對其每股普通股的比率從一(1) ADS代表25股普通股，調整爲一(1) ADS代表200股普通股。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。